INVA

Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update. "Our top priority in 2026 is advancing Armata's lead Staphylococcus aureus ("S. aureus") therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in complicated S. aureus bacteremia ("SAB")," said Dr. Deborah Birx, Chief Executive Officer of Armata. "We are focused on initiating a rigorously designed and operationally efficient study designed to support a future Biologics License Application ("BLA") submission and potential registration. If successful, AP-SA02 has the potential to offer an important new treatment option for patients facing this serious and often life-threatening infection. We believe this program will establish a foundation for expanding our phage platform into additional indications. Ultimately, we believe there is a significant opportunity for this innovative antibacterial technology to have a broad impact on antimicrobial resistance, which represents one of the significant public health challenges of modern medicine." "I also want to highlight other important recent developments including the granting by the U.S. Food and Drug Administration (the "FDA") of both Qualified Infectious Disease Product ("QIDP") and Fast Track Designation for AP-SA02. Additionally, the recent appointment of Dr. Daniel Gilmer to Armata's Board brings commercial leadership and experience as we continue to move toward potential registration and commercialization. We are pleased to have the ongoing backing of Innoviva, our largest shareholder who has supported us since 2020, in providing additional financing that will help us to advance AP-SA02, and we are continuing to pursue additional sources of funding, including non-dilutive sources," concluded Dr. Birx. First Quarter 2026 and Recent Developments: Clinical and Regulatory Preparations are ongoing to advance AP-SA02, a novel intravenously administered multi-phage therapeu...

Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +3.53%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.34 per share when it actually produced earnings of $1.94, delivering a surprise of +470.59%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Innoviva, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $97.99 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 1.83%. This compares to year-ago revenues of $88.63 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Innoviva shares have added about 13.3% since the beginning of the year versus the S&P 500's gain of 6%. While Innoviva has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Innoviva was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Bu...

BURLINGAME, Calif. (AP) — BURLINGAME, Calif. (AP) — Innoviva Inc. (INVA) on Wednesday reported net income of $186.6 million in its first quarter. On a per-share basis, the Burlingame, California-based company said it had profit of $2.22. Earnings, adjusted for non-recurring gains, were 44 cents per share. The biopharmaceutical company posted revenue of $98 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on INVA at https://www.zacks.com/ap/INVA

Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio BURLINGAME, Calif., May 06, 2026--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements. "We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress at IST, and meaningful value creation across our strategic healthcare assets," said Pavel Raifeld, Chief Executive Officer of Innoviva. "IST achieved 37% year-over-year net product sales growth in the first quarter of 2026, including 29% growth in U.S. sales." "We also remained active in executing our capital allocation priorities, including increased activity under our $125 million share repurchase program, underscoring our confidence in Innoviva’s long-term value proposition. Innoviva’s strong track record across its operating and strategic healthcare assets, coupled with significant cash resources and durable royalty inflows, positions us well for accretive capital deployment and long-term shareholder value creation throughout variable market environments," concluded Mr. Raifeld. Financial Highlights for the First Quarter of 2026 Total revenue: $98.0 million, yielding 11% growth compared to $88.6 million for the first quarter 2025. Royalty revenue: gross royalty revenue from Glaxo Group Limited ("GSK") was $58.6 million, compared to $61.3 million for the first quarter 2025. Net product sales: $41.4 million ($34.2 million U.S. and $7.2 million ex-US), representing 37% growth compared to $30.3 million in the same quarter of 2025. U.S. net product sales primarily consisted of $19.7 million from GIAPREZA®, $11.6 million from XACDURO®, and $2.5 million from XERAVA®. Income from operations: $38.2 million, compared to $41.4 million for the first quarter 2025, reflecting continued investment in commercial...

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full year IST achieved U.S. net product sales of $33.9 million for the fourth quarter and $119.2 million for the full year, representing 47% year-over-year growth IST product portfolio strengthened with U.S. FDA approval of NUZOLVENCE®, a first-in-class treatment for uncomplicated urogenital gonorrhea $125 million share repurchase program initiated in the fourth quarter BURLINGAME, Calif., February 25, 2026--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted select corporate progress and achievements. "2025 marked an excellent year for Innoviva, demonstrating strength across all areas of our business, with 15% revenue growth to over $400 million and net income exceeding $270 million. Our royalty business continued to provide stable and resilient cash flow, while IST generated 47% year-over-year U.S. sales growth to $119 million," said Pavel Raifeld, Chief Executive Officer of Innoviva. "We expanded our commercial portfolio with the successful mid-2025 launch of ZEVTERA in the U.S., received nominations for two of our products for the prestigious 2025 Prix Galien USA Award, and ended the year on an exciting note with the FDA approval of our fifth product, NUZOLVENCE, a single-dose oral treatment for uncomplicated urogenital gonorrhea that addresses a critical public health challenge in light of the global rise of gonococcal drug resistance. We are excited about our growth prospects and anticipate $150 million or more in IST U.S. net product sales in 2026." "Our portfolio of strategic assets remains a key platform for long-term growth and differentiation, demonstrated by significant advances and value creation at Armata Pharmaceuticals. Overall, we remain a well-capitalized company with multiple value-accretive capital deployment opportunities in our current business, novel assets, and capital strategies, including a recently announced $125 million share repurchase program. We...

BURLINGAME, Calif. (AP) — BURLINGAME, Calif. (AP) — Innoviva Inc. (INVA) on Wednesday reported net income of $164.2 million in its fourth quarter. The Burlingame, California-based company said it had profit of $1.94 per share. The biopharmaceutical company posted revenue of $114.6 million in the period. For the year, the company reported profit of $271.2 million, or $3.20 per share. Revenue was reported as $411.3 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on INVA at https://www.zacks.com/ap/INVA

Innoviva, Inc. (NASDAQ:INVA) just reported some strong earnings, and the market reacted accordingly with a healthy uplift in the share price. We did some analysis and think that investors are missing some details hidden beneath the profit numbers. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. One essential aspect of assessing earnings quality is to look at how much a company is diluting shareholders. In fact, Innoviva increased the number of shares on issue by 19% over the last twelve months by issuing new shares. Therefore, each share now receives a smaller portion of profit. To celebrate net income while ignoring dilution is like rejoicing because you have a single slice of a larger pizza, but ignoring the fact that the pizza is now cut into many more slices. You can see a chart of Innoviva's EPS by clicking here. Innoviva's net profit dropped by 56% per year over the last three years. On the bright side, in the last twelve months it grew profit by 97%. But EPS was less impressive, up only 93% in that time. Therefore, the dilution is having a noteworthy influence on shareholder returns. In the long term, earnings per share growth should beget share price growth. So it will certainly be a positive for shareholders if Innoviva can grow EPS persistently. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For the ordinary retail shareholder, EPS is a great measure to check your hypothetical "share" of the company's profit. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Alongside that dilution, it's also important to note that Innoviva's profit suffered from unusual items, which reduced profit by US$18m in the last twelve months. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expens...

Innoviva (INVA) posted its third-quarter earnings, showing significant jumps in both revenue and net income compared to last year. Investors are paying close attention, as these results come alongside important strategic moves. See our latest analysis for Innoviva. Innoviva’s recent surge is hard to miss. After revealing major earnings growth, the stock jumped 12.89% in a single day and is up more than 19% over the past month. While the short-term momentum has picked up, it’s worth noting that the total shareholder return over the past year was just 2.9%. Despite this, there was a robust 91% gain over five years, suggesting that longer-term investors have still benefited from Innoviva’s trajectory. Recent events have revived interest in the stock. If Innoviva’s momentum has you curious, consider broadening your scope and discover fast growing stocks with high insider ownership With the stock's recent rally and such remarkable earnings growth, the big question is whether Innoviva is still trading at an attractive valuation or if the market has already factored in the company's future prospects. Is this a genuine buying opportunity, or are investors now paying up for anticipated growth? Innoviva’s current price-to-earnings ratio of 10.2x sits below both its industry and peer group, suggesting relatively attractive pricing for investors at the latest closing price of $20.58 per share. The price-to-earnings (P/E) ratio represents what investors are willing to pay today for a dollar of current earnings. In pharmaceuticals and biotech, the P/E ratio is one of the most commonly referenced ways to compare stocks, since innovation and profit growth can vary significantly. A lower P/E, when fundamentals are solid, might indicate that the market is overlooking the company’s earnings profile. Innoviva’s earnings growth has recently outpaced both its own five-year average and industry trends. With a current P/E of 10.2x compared to the industry’s average of 17.8x, Innoviva trades at a substantial discount. Relative to the estimated fair price-to-earnings ratio of 16.4x, the market may be undervaluing potential future earnings as well. This level is considered a benchmark the stock could approach as sentiment or performance changes. Explore the SWS fair ratio for Innoviva Result: Price-to-Earnings of 10.2x (UNDERVALUED) However, slower revenue growth or unexpected industr...

Generated $63.4 million in revenue from durable royalties portfolio IST achieved U.S. net product sales of $29.9 million, representing 52% year-over-year growth Strengthened product portfolio with U.S. launch of ZEVTERA® Announced $125 million share repurchase program BURLINGAME, Calif., November 05, 2025--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achievements. "Innoviva delivered strong third-quarter performance across each area of our business. The royalties portfolio reaffirmed its resilience with 5% growth compared to last year, while IST delivered a third consecutive quarter of greater than 50% year-over-year U.S. sales growth. We are encouraged by early market receptivity for ZEVTERA® following its U.S. launch over the summer and look forward to zoliflodacin’s December 15 PDUFA date," said Pavel Raifeld, Chief Executive Officer of Innoviva. "Across the broader portfolio, we saw meaningful value creation from our strategic investments, including Armata Pharmaceuticals, and continued to thoughtfully deploy capital in areas of opportunity and market dislocation. The $125 million share repurchase program underscores our confidence in Innoviva’s prospects, supported by the strength of our balance sheet and cashflows, as we strive to create value for our shareholders," concluded Mr. Raifeld. Financial Highlights Total revenue: Total revenue for the third quarter 2025 was $107.8 million, representing 20% growth compared to total revenue of $89.5 million for the third quarter 2024. Royalty revenue: Third quarter 2025 gross royalty revenue from Glaxo Group Limited ("GSK") was $63.4 million, compared to $60.5 million for the third quarter 2024. Net product sales: Third quarter 2025 net product sales totaled $47.3 million, consisting of $29.9 million in U.S. net product sales and $17.4 million in ex-U.S. net product sales, compared to $27.8 million in net product sales for the third quarter 2024. U.S. net product sales included $18.2 million from GIAPREZA®, $8.5 million from...

BURLINGAME, Calif. (AP) — BURLINGAME, Calif. (AP) — Innoviva Inc. (INVA) on Wednesday reported profit of $89.9 million in its third quarter. On a per-share basis, the Burlingame, California-based company said it had net income of $1.08. The biopharmaceutical company posted revenue of $107.8 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on INVA at https://www.zacks.com/ap/INVA

Innoviva (INVA) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +134.78%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.57 per share when it actually produced earnings of $0.77, delivering a surprise of +35.09%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Innoviva, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $107.8 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 14.78%. This compares to year-ago revenues of $89.51 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Innoviva shares have added about 4.6% since the beginning of the year versus the S&P 500's gain of 15.1%. While Innoviva has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Innoviva was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank...

Explore Innoviva's Fair Values from the Community and select yours The market for Innoviva, Inc.'s (NASDAQ:INVA) shares didn't move much after it posted weak earnings recently. Our analysis suggests that while the profits are soft, the foundations of the business are strong. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth. For the year to June 2025, Innoviva had an accrual ratio of -0.19. That implies it has very good cash conversion, and that its earnings in the last year actually significantly understate its free cash flow. In fact, it had free cash flow of US$196m in the last year, which was a lot more than its statutory profit of US$38.6m. Innoviva's free cash flow improved over the last year, which is generally good to see. However, that's not all there is to consider. The accrual ratio is reflecting the impact of unusual items on statutory profit, at least in part. View our latest analysis for Innoviva That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Innoviva's profit was reduced by unusual items worth US$113m in the last twelve months, and this helped it produce high cash conversion, as reflected by its unusual items. This is what you'd expect to see where a company has a non-cash charge reducing paper profits. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner...